Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-01-10

FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Biocon Pharma Inc.)

View source ↗

Summary

FDA approved Biocon Pharma Inc.'s supplemental application for atorvastatin calcium, authorizing its continued marketing as a generic statin therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ATORVASTATIN CALCIUM (atorvastatin calcium)

Snippet

SUPPL AP for ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)